Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | IM / RA |
administered two doses of SHINGRIX in the consumers right arm; This non-serious case was reported by a consumer via call center representative and described the occurrence of overdose in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included breast cancer, lung nodule and lung neoplasm surgery. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 28-DEC-2024, the patient received the 2nd dose of Shingrix (intramuscular, right arm) .5 ml. On 28-DEC-2024, an unknown time after receiving Shingrix, the patient experienced overdose (Verbatim: administered two doses of SHINGRIX in the consumers right arm). On 28-DEC-2024, the outcome of the overdose was not applicable. Additional Information: GSK Receipt Date: 22-APR-2025 On 28 December 2024 the patient presented to the pharmacy for her first dose of Shingrix. The vaccinating healthcare professional administered two doses of Shingrix in the patient's right arm which led to overdose. The consumer reported that she was diagnosed with breast cancer in 2016 and also reported she had a nodule was removed from her lung in 2012. Other Products were reported as no
Medical History/Concurrent Conditions: Breast cancer; Lung neoplasm surgery; Lung nodule
SHINGRIX